Evidence map›Paper›PMID 22787192›Full record

ArticleClinical and vaccine immunology : CVI2012

Enhanced priming of adaptive immunity by Mycobacterium smegmatis mutants with high-level protein secretion.

Natalie Taylor, Faith Bahunde, Afton Thompson, Jae-Sung Yu, William R Jacobs, Norm L Letvin, Barton F Haynes, Sunhee Lee

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Discovery ofAntibiotics (Basel, Switzerland) · 2024
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Natalie TaylorDuke University School of Medicine, Human Vaccine Institute, Durham, NC, USA.
Faith Bahunde
Afton Thompson
Jae-Sung Yu
William R Jacobs
Norm L Letvin
Barton F Haynes
Sunhee Lee
Duke University · USAlbert Einstein College of Medicine · USHarvard University · US

Funding

Technology Application to Enhance Discharge Referral Decision SupportR44NR013609 · NINR · RIGHTCARE SOLUTIONS, INC. · PI HEIL, ERIC · 2014 to 2015
$1.5M
Technology Application to Enhance Discharge Referral Decision SupportR43NR013609 · NINR · RIGHTCARE SOLUTIONS, INC. · PI BHASKER, MRINAL, BOWLES, KATHRYN HELENE · 2012 to 2013
$187k
NINR NIH HHS NR-13609NINR NIH HHS R43 NR013609NINR NIH HHS R44 NR013609
6 · The paper itself

Abstract

Mycobacteria have features that make them attractive as potential vaccine vectors. The nonpathogenic and rapidly growing Mycobacterium smegmatis can express both Mycobacterium tuberculosis antigens and heterologous antigens from other pathogens, and it has been used as a viable vector for the development of live vaccines. In order to further improve antigen-specific immunogenicity of M. smegmatis, we screened a random transposon mutant library for mutants displaying enhanced efficiency of protein secretion ("high secretors") and isolated 61 mutants showing enhanced endogenic and transgenic protein secretion. Sequence analysis identified a total of 54 genes involved in optimal secretion of insert proteins, as well as multiple independent transposon insertions localized within the same genomic loci and operons. The majority of transposon insertions occurred in genes that have no known protein secretion function. These transposon mutants were shown to prime antigen-specific CD8(+) T cell responses better than the parental strain. Specifically, upon introducing the simian immunodeficiency virus (SIV) gag gene into these transposon mutant strains, we observed that they primed SIV Gag-specific CD8(+) T cell responses significantly better than the control prime immunization in a heterologous prime/boost regimen. Our results reveal a dependence on bacterial secretion of mycobacterial and foreign antigens for the induction of antigen-specific CD8(+) T cells in vivo. The data also suggest that these M. smegmatis transposon mutants could be used as novel live attenuated vaccine strains to express foreign antigens, such as those of human immunodeficiency virus type 1 (HIV-1), and induce strong antigen-specific T cell responses.

Indexed as

AnimalsBacterial ProteinsBacterial VaccinesCD8-Positive T-LymphocytesDNA Transposable ElementsFemaleGene Products, gagMiceMice, Inbred C57BLMutagenesis, InsertionalMycobacterium smegmatisMycobacterium tuberculosisSAIDS VaccinesSimian Immunodeficiency VirusVaccines, AttenuatedBacterial ProteinsBacterial VaccinesDNA Transposable ElementsGene Products, gagSAIDS VaccinesVaccines, Attenuated

Identifiers

PMID22787192
PMCPMC3428392
OpenAlexW2111913889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.